[

glenmark pharmaceuticals

]

Glenmark Life Sciences shares make muted debut, list at 4% premium

Glenmark Life Sciences shares edged higher on debut on stock markets as they rose to 751 per share, a premium over the issue price of 720 apiece.
Glenmark Life Sciences shares listing comes days after its initial public offering (IPO) was oversubscribed 44 times. (File Photo)
Glenmark Life Sciences shares listing comes days after its initial public offering (IPO) was oversubscribed 44 times. (File Photo)
Published on Aug 06, 2021 10:59 AM IST
Copy Link
Byhindustantimes.com | Written by Meenakshi Ray, New Delhi

Glenmark, SaNOtize sign deal for Covid nasal spray in India, Asian countries

Glenmark has said the nasal spray is designed to kill the coronavirus in the upper airways, preventing it from incubating and spreading to the lungs.
Glenmark chairperson and managing director Glenn Saldanha said the partnership with SaNOtize reflects Glenmark's focused approach against Covid-19. (Representative Photo)
Glenmark chairperson and managing director Glenn Saldanha said the partnership with SaNOtize reflects Glenmark's focused approach against Covid-19. (Representative Photo)
Published on Aug 02, 2021 12:01 PM IST
Copy Link
Byhindustantimes.com | Written by Meenakshi Ray, New Delhi

Glenmark Life Sciences IPO fully subscribed on Day 1

Glenmark Life Sciences IPO size was reduced to 1.5 crore equity shares after the company garnered 454 crore from anchor investors on Monday.
Glenmark Life Sciences shares were available at a premium of <span class='webrupee'>₹</span>110 in the grey market, according to market observers. (Representative Photo)
Glenmark Life Sciences shares were available at a premium of 110 in the grey market, according to market observers. (Representative Photo)
Published on Jul 27, 2021 12:13 PM IST
Copy Link
Byhindustantimes.com | Written by Meenakshi Ray, New Delhi

Glenmark introduces cheaper drug for lung fibrosis in India

It is also one of the long-term complications that patients, who have recovered from coronavirus disease (Covid-19), are likely to suffer from, according to doctors
Nintedanib is approved by the Central Drugs Standard Control Organisation (CDSCO) for the treatment of Idiopathic (unknown cause) PF (IPF).(Getty Images/iStockphoto)
Nintedanib is approved by the Central Drugs Standard Control Organisation (CDSCO) for the treatment of Idiopathic (unknown cause) PF (IPF).(Getty Images/iStockphoto)
Published on Oct 14, 2020 12:54 PM IST
Copy Link
Hindustan Times, New Delhi | ByRhythma Kaul

Glenmark’s Favipiravir drug shows encouraging results in Phase 3 clinical trial

The company said that patients randomised to Favipiravir treatment arm reported faster clinical cure and faster viral clearance than those randomized to the routine care group.
About 69.8 per cent of patients in the Favipiravir treatment arm achieved clinical cure by Day 4, which was statistically significant compared to 44.9 per cent observed in the control arm.(ANI file photo)
About 69.8 per cent of patients in the Favipiravir treatment arm achieved clinical cure by Day 4, which was statistically significant compared to 44.9 per cent observed in the control arm.(ANI file photo)
Published on Jul 23, 2020 10:07 AM IST
Copy Link
Asian News International | ByAsian News International| Posted by: Harshit Sabarwal

Glenmark Pharma cuts price of Covid-19 drug by 27 percent to Rs 75 per tablet

Glenmark Pharmaceuticals had launched FabiFlu last month at a price of Rs 103 per tablet.
Glenmark Pharmaceuticals cut antiviral drug Favipiravir’s price on Monday(REUTERS)
Glenmark Pharmaceuticals cut antiviral drug Favipiravir’s price on Monday(REUTERS)
Updated on Jul 13, 2020 01:08 PM IST
Copy Link
New Delhi | ByPress Trust of India | Posted by Prashasti Singh

Glenmark Pharmaceuticals shares soar 20% after Covid-19 drug launch

Glenmark Pharmaceuticals on Saturday said it has launched antiviral drug FabiFlu for the treatment of patients with mild to moderate Covid-19 at a price of about Rs 103 per tablet.
Glenmark Pharmaceuticals has launched antiviral drug Favipiravir for treatment of Covid-19 patients.(ANI File Photo)
Glenmark Pharmaceuticals has launched antiviral drug Favipiravir for treatment of Covid-19 patients.(ANI File Photo)
Updated on Jun 22, 2020 12:46 PM IST
Copy Link
New Delhi | ByPress Trust of India | Posted by Kanishka Sarkar

Glenmark launches Covid-19 drug at Rs 103 per tablet

The drug will be available as a 200 mg tablet at a maximum retail price (MRP) of Rs 3,500 for a strip of 34 tablets, Glenmark Pharmaceuticals said.
The drug will be available as a prescription-based medication for Rs 103/tablet, with recommended dose being 1,800 mg twice on day one, followed by 800 mg twice daily up to day 14.(Bloomberg)
The drug will be available as a prescription-based medication for Rs 103/tablet, with recommended dose being 1,800 mg twice on day one, followed by 800 mg twice daily up to day 14.(Bloomberg)
Updated on Jun 20, 2020 09:33 PM IST
Copy Link
New Delhi | ByPress Trust of India| Posted by Susmita Pakrasi

Glenmark gets DGCI nod for clinical trial

Favipiravir, sold under the brand name Avigan of Fujifilm Toyama Chemical Co. Ltd, Japan, a subsidiary of Fujifilm Corporation, is an antiviral medication used to treat influenza in Japan.
The DCGI approved to conduct trials on Favipiravir antiviral tablets on Covid-19 patients, making Glenmark the first pharmaceutical firm in India to be given an approval to start the trial.(AFP)
The DCGI approved to conduct trials on Favipiravir antiviral tablets on Covid-19 patients, making Glenmark the first pharmaceutical firm in India to be given an approval to start the trial.(AFP)
Published on May 01, 2020 03:49 AM IST
Copy Link
Hindustan Times, New Delhi | ByRhythma Kaul
SHARE
Story Saved
×
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Saturday, November 27, 2021